BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15800715)

  • 21. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia.
    Choi CW; Sung HJ; Park KH; Yoon SY; Kim SJ; Oh SC; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS
    Am J Hematol; 2003 Aug; 73(4):263-6. PubMed ID: 12879430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
    von Minckwitz G; Schwenkglenks M; Skacel T; Lyman GH; Pousa AL; Bacon P; Easton V; Aapro MS
    Eur J Cancer; 2009 Mar; 45(4):608-17. PubMed ID: 19110415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [High risk febrile neutropenia in acute leukemia. The experience of a public hospital. National Program of Antineoplastic Drugs in Adult, Hospital del Salvador, 1991-2001].
    Puga B; Puga I; Cabrera ME; Undurraga MS; Guerra C; Urrejola G; Toro P
    Rev Med Chil; 2003 Sep; 131(9):1023-30. PubMed ID: 14635589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Which one is a risk factor for chemotherapy-induced febrile neutropenia in childhood solid tumors: early lymphopenia or monocytopenia?
    Oguz A; Karadeniz C; Ckitak EC; Cil V
    Pediatr Hematol Oncol; 2006 Mar; 23(2):143-51. PubMed ID: 16651243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies.
    Levenga TH; Timmer-Bonte JN
    Br J Haematol; 2007 Jul; 138(2):146-52. PubMed ID: 17593021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
    Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific enumeration of the probiotic strain Enterococcus faecium NCIMB 10415 in the intestinal tract and in faeces of piglets and sows.
    Macha M; Taras D; Vahjen W; Arini A; Simon O
    Arch Anim Nutr; 2004 Dec; 58(6):443-52. PubMed ID: 15732577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.
    Klastersky J; Paesmans M; Georgala A; Muanza F; Plehiers B; Dubreucq L; Lalami Y; Aoun M; Barette M
    J Clin Oncol; 2006 Sep; 24(25):4129-34. PubMed ID: 16943529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical evaluation of cefozopran as treatment for febrile neutropenia].
    Saito T; Hara M; Shinagawa K; Nawa Y; Nakase K; Takeuchi M; Miyata A; Fukuda S; Sunami K; Imajoh K; Yano T; Kojima K; Teshima T; Fujii N; Ishimaru F; Ikeda K; Harada M; Tanimoto M
    Gan To Kagaku Ryoho; 2004 Jan; 31(1):61-5. PubMed ID: 14750323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy-induced neutropenia in lung cancer patients: the role of antibiotic prophylaxis.
    Kouranos V; Dimopoulos G; Vassias A; Syrigos KN
    Cancer Lett; 2011 Dec; 313(1):9-14. PubMed ID: 21955615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Consensus: Rational approach towards the patient with cancer, fever and neutropenia].
    Santolaya ME; Rabagliati R; Bidart T; Payá E; Guzmán AM; Morales R; Braun S; Bronfman L; Ferrés M; Flores C; García P; Letelier LM; Puga B; Salgado C; Thompson L; Tordecilla J; Zubieta M; ;
    Rev Chilena Infectol; 2005; 22 Suppl 2():S79-113. PubMed ID: 16311689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment with Protein C of febrile neutropenia in pediatric patients during cancer therapy.
    Giordano P; Cecinati V; Delvecchio GC; Arcamone G; De Leonardis F; Grassi M; Brescia LP; Santoro N; De Mattia D
    Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):293-8. PubMed ID: 19235536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
    Lyman GH; Lalla A; Barron RL; Dubois RW
    Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
    Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
    J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
    Ugarte-Torres A; Villasis-Keever A; Hernández-Bribiesca ME; Crespo-Solis E; Ruiz-Palacios GM; Sifuentes-Osornio J; Ponce-De-León-Garduño A
    Rev Invest Clin; 2006; 58(6):547-54. PubMed ID: 17432285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.